Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051722 · ClinicalTrials.gov registry record
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
A clinical trial of Ovarian Cancer and Endometrial Cancer, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 3,110
- Enrollment target
- 20
- Study locations
NCT05051722 is a study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 3,110 participants, above the 719-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (333% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05051722, a study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 3,110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Vaginal Fluid Collection
- DIAGNOSTIC_TEST Blood Collection
Study Locations (20)
Florida
- Mayo Clinic - Jacksonville
- My GYN Care - Miami
- Genoma Research, Inc. - Miami
- Orlando Health - Orlando
- Signature Women's Healthcare, LLC - Pembroke Pines
- Sarasota Memorial Health Care System - Sarasota
Illinois
- University of Chicago - Chicago
- Providea Health Partners, LLC - Evergreen Park
New York
- The Woman's Health Pavilion - Howard Beach
- The Woman's Health Pavilion - Westbury
Texas
- Total Women's Care of the Heights - Houston
- Medical Colleagues of Texas, LLP - Katy
Arizona
- Mayo Clinic - Phoenix
Georgia
- Piedmont Healthcare - Atlanta
Louisiana
- Ochsner Clinic Foundation - New Orleans
Michigan
- Valley OB-GYN Clinic - Saginaw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,110 participants |
| Start Date | 2021-08-03 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05051722
The ClinicalTrials.gov registry entry for NCT05051722 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,110 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 719-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (333% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vaginal Fluid Collection is the first listed.
NCT05051722 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05051722 about?
NCT05051722 is a clinical study titled "Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer". The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop...
What is the current status of trial NCT05051722?
This trial is currently recruiting. The enrollment target is 3,110 participants. The study started on 2021-08-03. Estimated completion is 2027-06-30.
What conditions does trial NCT05051722 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Cervical Dysplasia, Atypical Endometrial Hyperplasia.
What interventions are being tested in trial NCT05051722?
The interventions under investigation include: Vaginal Fluid Collection (DIAGNOSTIC_TEST), Blood Collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05051722?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05051722 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.